ZYN Q2 2026: 2.9 Billion Pouches, $11B Revenue and EU Flavour Ban Deadline

Two major stories are reshaping the nicotine pouch industry this week. First: Philip Morris International delivered record Q2 results on July 22, 2026, with ZYN shipments reaching 2.9 billion pouches and total revenues surpassing $11 billion for the first time. Second: the EU TPD3 public consultation closes on August 14 — in 20 days — and the outcome could ban flavoured nicotine pouches across Europe by 2029. Here is everything that matters.

PMI Q2 2026: The Headline Numbers

Philip Morris International reported its strongest quarterly performance on record on July 22, 2026. Total net revenues reached $11.2 billion — up 10.4% reported and 7.6% organically — the first time PMI has crossed the $11 billion mark in a single quarter.

Adjusted diluted EPS came in at $2.20, significantly beating analyst consensus estimates of around $2.03–2.05. Operating income grew 22%, while adjusted operating income reached $4.8 billion. PMI shares rose approximately 5% in early trading on the day of the announcement.

The company maintained its full-year guidance, targeting organic net revenue growth of 5% to 7% and adjusted diluted EPS growth of 9.5% to 11.5% — reaffirming confidence in a strong second half driven by accelerated ZYN investment.

ZYN Specifically: What the Q2 Numbers Mean

For nicotine pouch users and industry watchers, the ZYN data is the headline within the headline. ZYN shipped 2.9 billion pouches in Q2 2026 — up 2% year-on-year — despite the comparison being skewed by an approximately 150 million pouch inventory restocking tailwind in Q2 2025. The underlying offtake trend was described by PMI management as "flat to slightly growing" in the US.

Internationally, the picture is stronger. ZYN international shipments grew +6% in H1 2026, and +32% excluding the Nordic markets (where the legacy snus business is declining). ZYN now operates in 60 markets globally, up from fewer than 30 two years ago. Key growth markets highlighted by PMI include Pakistan, Poland and the UK.

Modern oral tobacco-free nicotine products (ZYN's category) showed +14.7% volume growth globally. The headlined "oral SFP volume decrease" of 7% was entirely driven by traditional snus declining in Nordic markets — a completely separate product category. Nicotine pouches specifically are growing robustly.

Browse the full ZYN collection at The Snus Outlet — all strengths and flavours in stock with free EU shipping on orders over €99.

PMI vs the Market: How ZYN Compares to VELO and LOOP

Brand	Parent Company	Q2 2026 Snapshot	Key Markets	Competitive Position
ZYN	PMI	2.9B pouches Q2, 60 markets	US, Europe, Pakistan, UK	Global leader, FDA MRTP authorised
VELO	BAT	No Q2 update (BAT reports Aug)	Europe, US, Africa	Largest EU distribution footprint
LOOP / XQS	Swedish Match / PMI	Included in PMI oral SFP data	Nordics, EU	Premium EU brands, growing online
ALP	Turning Point Brands	Phase 1 live July 2026	UK, Ireland, Greece, Switzerland, Romania	Fastest new EU entrant, moist format

US ZYN: Recovery After a Difficult Q1

In the US market specifically, ZYN had a challenging Q1 2026 that weighed on the first half performance. Q2 showed a significant sequential improvement — US net revenues improved +38% versus Q1, and adjusted gross profit improved +46%. ZYN shipments grew +2% year-on-year to 2.9 billion pouches.

PMI management described the US competitive landscape as "uneven" but committed to accelerating investment in ZYN brand equity and portfolio expansion in the second half of 2026. The June 30, 2026 FDA MRTP authorisation — confirming lower risk than cigarettes for mouth cancer, lung cancer and heart disease — gives PMI a powerful marketing tool for the US market in H2.

New ZYN Ultra variants launched in Q2 also contributed to early shipment volumes, signalling a continued product expansion strategy beyond the core Spearmint and Cool Mint range.

EU TPD3: The August 14 Deadline — What Actually Happens?

While PMI celebrated a record quarter, the regulatory backdrop in Europe is evolving fast. The European Commission's public consultation on TPD3 — the planned revision of the EU Tobacco Products Directive — closes on August 14, 2026. That is 20 days from today.

TPD3 would be the first EU law to explicitly cover nicotine pouches. The most controversial proposal under discussion is a blanket flavour ban — eliminating mint, citrus, berry, coffee and all other flavours across the EU, leaving only unflavoured or tobacco-flavoured products on shelves. Twelve member states, led by Ireland, formally pushed for flavour restrictions at the June 20, 2026 EU Health Council meeting.

The legislative process works as follows:

1. Consultation closes August 14, 2026 — Commission collects public input
2. Commission publishes legislative proposal — expected Q4 2026
3. European Parliament + Council negotiate — typically 1–2 years
4. Member state transposition — 2-year implementation period after adoption
5. Earliest enforcement: 2029–2030

Critically: nothing changes in 2026 or 2027. The consultation closing on August 14 is an information-gathering step, not a regulation. Current products, flavours and sales continue completely unaffected. Anyone can submit feedback directly to the European Commission consultation — individual consumers and industry participants are equally eligible.

What TPD3 Could Mean for Your Favourite Brands

If the most aggressive flavour ban scenario passes — which is not guaranteed — the following could disappear from EU shelves by 2030:

• ZYN Cool Mint, Spearmint, Citrus — all non-tobacco flavours at risk
• VELO Freeze, Icy Mint, Tropical Burst — same risk applies
• LOOP Jalapeño Lime, Mint Mania, Habanero Mint — all flavoured variants
• XQS Blueberry Mint, Arctic Mint — mint and fruit classifications both at risk
• ZEUS Arctic Blast, Citrus Storm — all flavoured products

Explore the full 2026 top picks collection while current flavours are still available. The outlet deals section offers bulk-buy discounts — free EU shipping on orders over €99.

The Counterargument: ZYN's FDA MRTP and Harm Reduction

The FDA's June 30, 2026 authorisation of ZYN as a modified-risk tobacco product is likely to feature prominently in the EU consultation response from industry groups. PMI and public health harm reduction advocates will argue that flavoured nicotine pouches help smokers transition away from cigarettes — and that banning them removes a key tool in the smoke-free transition toolkit.

The precedent matters: flavour bans in the EU for e-cigarettes have been associated in some markets with users switching back to traditional cigarettes. Applying similar restrictions to nicotine pouches could produce the same outcome. This argument is central to industry submissions to the Commission before August 14.

Frequently Asked Questions

How much did ZYN grow in Q2 2026?

ZYN shipped 2.9 billion pouches in Q2 2026, a 2% year-on-year increase. Internationally (excluding the Nordics), ZYN grew +32% in the first half of 2026. PMI confirmed it will accelerate investment in ZYN brand equity and new product variants in the second half of 2026, following a strong Q2 recovery in the US.

Did PMI beat earnings estimates in Q2 2026?

Yes. PMI reported adjusted diluted EPS of $2.20 against analyst consensus of approximately $2.03–2.05, and total net revenues of $11.2 billion against estimates around $10.56–10.60 billion. It was the first time PMI generated over $11 billion in a single quarter. Shares rose approximately 5% on July 22, 2026.

What is the EU TPD3 consultation and when does it close?

TPD3 is the European Commission's planned revision of the EU Tobacco Products Directive 2014/40/EU. For the first time, the revision would explicitly cover nicotine pouches, potentially introducing flavour bans, nicotine caps and packaging rules. The public consultation is open until August 14, 2026 — anyone can submit feedback. A formal legislative proposal is expected by the end of 2026, with enforcement unlikely before 2029–2030.

Will EU flavour bans on nicotine pouches actually happen?

It is possible but not certain. Twelve member states have formally pushed for flavour restrictions, but the legislative process is long — consultation closes August 14, the Commission then drafts a proposal (expected Q4 2026), Parliament and Council negotiate for 1–2 years, and member states then have a transposition period. The realistic earliest date for any flavour ban to take effect is 2029–2030. Current flavours remain on sale throughout this entire process.

How does ZYN's FDA MRTP affect the EU debate?

The FDA's June 30, 2026 Modified Risk Tobacco Product authorisation confirmed that ZYN pouches pose lower risks for mouth cancer, lung cancer and heart disease compared to cigarettes. PMI and harm reduction advocates will use this evidence in their EU consultation submissions to argue that nicotine pouches should be supported — not restricted — as smoking cessation tools. The FDA decision has significant political weight in EU regulatory discussions.

Final Thoughts

PMI's Q2 results are unambiguously strong: ZYN is growing globally, revenues are at record levels, and the FDA MRTP authorisation gives the brand a meaningful credibility boost heading into the EU regulatory battle. The August 14 TPD3 consultation deadline is the next major event to watch — but European consumers and industry alike have until then to make their voices heard.

In the meantime, every ZYN flavour remains available at The Snus Outlet. Stock up on your favourite flavours now — with free EU shipping on orders over €99 and tracked delivery in 2–7 days across Europe.